Abstract
1. The efficacy and acceptability of enalapril were assessed in a double-blind, randomised, placebo controlled cross-over study in 21 patients with primary Raynaud's phenomenon. 2. Skin temperature was assessed by thermocouples in response to a 15 degrees C cold water challenge as an index of digital blood flow. 3. Following enalapril there were no significant changes in the number and severity of Raynaud's attacks, and no subjective benefit from treatment as measured by visual analogue scales, 5 point rating scales, and skin temperature response to cold challenge when compared with placebo. 4. Enalapril in a dose of 20 mg daily is ineffective in the management of primary Raynaud's phenomenon.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Blunt R. J., Porter J. M. Raynaud syndrome. Semin Arthritis Rheum. 1981 May;10(4):282–308. doi: 10.1016/0049-0172(81)90006-8. [DOI] [PubMed] [Google Scholar]
- Havelka J., Boerlin H. J., Studer A., Greminger P., Tenschert W., Luescher T., Siegenthaler W., Vetter W., Walger P., Vetter H. Long-term experience with captopril in severe hypertension. Br J Clin Pharmacol. 1982;14 (Suppl 2):71S–76S. doi: 10.1111/j.1365-2125.1982.tb02060.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hills M., Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979 Jul;8(1):7–20. doi: 10.1111/j.1365-2125.1979.tb05903.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Janini S. D., Scott D. G., Coppock J. S., Bacon P. A., Kendall M. J. Enalapril in Raynaud's phenomenon. J Clin Pharm Ther. 1988 Apr;13(2):145–150. doi: 10.1111/j.1365-2710.1988.tb00171.x. [DOI] [PubMed] [Google Scholar]
- Madsen J. L., Hvidt S. Raynaud's sygdom behandlet med kaptopril (Capoten). En randomiseret dobbeltblind overkrydsningsundersøgelse. Ugeskr Laeger. 1984 Sep 3;146(36):2695–2697. [PubMed] [Google Scholar]
- Miyazaki S., Miura K., Kasai Y., Abe K., Yoshinaga K. Relief from digital vasospasm by treatment with captopril and its complete inhibition by serine proteinase inhibitors in Raynaud's phenomenon. Br Med J (Clin Res Ed) 1982 Jan 30;284(6312):310–311. doi: 10.1136/bmj.284.6312.310. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rustin M. H., Almond N. E., Beacham J. A., Brooks R. J., Jones D. P., Cooke E. D., Dowd P. M. The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon. Br J Dermatol. 1987 Dec;117(6):751–758. doi: 10.1111/j.1365-2133.1987.tb07356.x. [DOI] [PubMed] [Google Scholar]
- Studer A., Lüscher T., Siegenthaler W., Vetter W. Captopril in various forms of severe therapy-resistant hypertension. Klin Wochenschr. 1981 Jan 15;59(2):59–67. doi: 10.1007/BF01477284. [DOI] [PubMed] [Google Scholar]
- Tosi S., Marchesoni A., Messina K., Bellintani C., Sironi G., Faravelli C. Treatment of Raynaud's phenomenon with captopril. Drugs Exp Clin Res. 1987;13(1):37–42. [PubMed] [Google Scholar]
- Trübestein G., Wigger E., Trübestein R., Ludwig M., Wilgalis M., Stumpe K. O. Behandlung des Raynaud-Syndroms mit Captopril. Dtsch Med Wochenschr. 1984 Jun 1;109(22):857–860. doi: 10.1055/s-2008-1069287. [DOI] [PubMed] [Google Scholar]
- Waller D. G., Challenor V. F., Francis D. A., Roath O. S. Clinical and rheological effects of nifedipine in Raynaud's phenomenon. Br J Clin Pharmacol. 1986 Oct;22(4):449–454. doi: 10.1111/j.1365-2125.1986.tb02916.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zusman R. M. Effects of converting-enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity. Am J Kidney Dis. 1987 Jul;10(1 Suppl 1):13–23. [PubMed] [Google Scholar]